HUGEL announced on the 13th that its consolidated operating profit last year was 166.3 billion won, marking a 41.2% increase compared to the previous year. During the same period, sales rose by 16.7% year-on-year to 373 billion won.
The company noted that the botulinum toxin "Botulax" drove performance growth. Botulax sales last year were 203.2 billion won, an increase of 20.2% compared to the previous year. Of this, overseas sales in the United States, Europe, and the Asia-Pacific region grew by 39.6% year-on-year.
The hyaluronic acid (HA) filler product line (The Chaeum, Biorizen) also recorded annual sales of 127.6 billion won last year. Overseas sales increased by 13.2% year-on-year due to growth in China, Europe, and the Middle East and North Africa (MENA) regions. The derma cosmetic product line (Wellage, Biorizen BR) also showed robust sales growth.
HUGEL is set to launch the botulinum toxin in the U.S. market in the first half of this year. The plan is to achieve a 10% market share in the U.S. medical aesthetic market within three years.
A representative from HUGEL said, "Our flagship products, the botulinum toxin and HA fillers, along with cosmetics as a new growth engine, achieved significant growth last year, leading to the highest sales, operating profit, and net profit in the company's history. This year, we will continue to grow steadily across Asia-Pacific and Europe, including new markets like North America and MENA, solidifying our position as a global top-notch corporation."